New salicylates as maintenance treatment in ulcerative colitis.
نویسندگان
چکیده
منابع مشابه
New Keys to Maintenance Treatment in Ulcerative Colitis
Maintenance treatment in ulcerative colitis often fails to prevent flares and long term complications. The first key to maintenance is to use effective therapy, even when patients become asymptomatic. The second key is to communicate the importance of adherence to patients, and to help them achieve long term adherence. Simplified dosing schedules are of some benefit, but the bond between patien...
متن کاملNew Keys to Maintenance Treatment in Ulcerative Colitis
Maintenance treatment in ulcerative colitis often fails to prevent flares and long term complications. The first key to maintenance is to use effective therapy, even when patients become asymptomatic. The second key is to communicate the importance of adherence to patients, and to help them achieve long term adherence. Simplified dosing schedules are of some benefit, but the bond between patien...
متن کاملNew keys to maintenance treatment in ulcerative colitis.
Maintenance treatment in ulcerative colitis often fails to prevent flares and long term complications. The first key to maintenance is to use effective therapy, even when patients become asymptomatic. The second key is to communicate the importance of adherence to patients, and to help them achieve long term adherence. Simplified dosing schedules are of some benefit, but the bond between patien...
متن کاملSURGICAL TREATMENT OF ULCERATIVE COLITIS
This is a preliminary report of 28 patients with ulcerative colitis who we surgically treated with "J" pouch endorectal pull-through operation from 1978 to 1996. All patients are continent with a median stool frequency of 4 times per day, no night soilage. low postoperative complications and one mortality due to pulmonary embolism.
متن کاملVedolizumab as induction and maintenance therapy for ulcerative colitis.
BACKGROUND Gut-selective blockade of lymphocyte trafficking by vedolizumab may constitute effective treatment for ulcerative colitis. METHODS We conducted two integrated randomized, double-blind, placebo-controlled trials of vedolizumab in patients with active disease. In the trial of induction therapy, 374 patients (cohort 1) received vedolizumab (at a dose of 300 mg) or placebo intravenousl...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Gut
سال: 1994
ISSN: 0017-5749
DOI: 10.1136/gut.35.9.1155